With increasing prioritization for neuroscience discovery, huge biopharma is investing in expanding its departments, focusing on glial biology, neuroinflammatory biomarkers, and optimizing various approaches to target the likes of LRKK2, TREM2, and more. Therefore, there was a great amount of novel and promising research to be discussed in 2023.

Uniting 100+ neuroinflammation and neuroimmunology experts across all neurological indications, including AD, PD, ALS, and MS, the 5th Annual Neuroimmunology Drug Development meeting returned to Boston to host discovery, preclinical, translational, and clinical experts from the likes of Genentech, Muna Therapeutics, Biogen, Janssen, Bristol Myers Squibb, Sanofi, Takeda, and Roche.

With new speakers from the hottest biopharma in neuroimmunology delivering, a comprehensive program of pioneering and cutting-edge content, don’t miss your crucial chance to join this niche audience of innovators with a shared desire to explore strategy, creation, and implementation of research, biomarker, and clinical hypothesis testing in neuroimmunology.